| Literature DB >> 26600222 |
Saleh Alqahtani1, Mark Sulkowski2.
Abstract
Development of antiviral agents that target the hepatitis C virus (HCV) has improved the success and tolerability of treatment, especially for patients with HCV genotype 1 infection. The new treatment options mean that clinicians are better able to prevent complications from chronic HCV infection. The field of direct-acting antiviral therapies for HCV infection continues to advance at a rapid pace, and many more potential treatment regimens are being investigated. This article presents a summary of the current treatments available for patients infected with HCV genotype 1 and looks ahead to those that may play a role in the future.Entities:
Keywords: Cirrhosis; Hepatitis; Hepatitis C; Ledipasvir antiviral; Simeprevir; Sofosbuvir
Mesh:
Substances:
Year: 2015 PMID: 26600222 DOI: 10.1016/j.gtc.2015.06.001
Source DB: PubMed Journal: Gastroenterol Clin North Am ISSN: 0889-8553 Impact factor: 3.806